Meeting
2020 Gastrointestinal Cancers Symposium
First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).
Authors
Zev A. Wainberg
UCLA School of Medicine, Los Angeles, CA
Zev A. Wainberg , Jennifer Robinson Diamond , Giuseppe Curigliano , Sanjeev Deva , Johanna C. Bendell , Sae-Won Han , Aparna Kalyan , Jarushka Naidoo , Richard D. Kim , Sandip Pravin Patel , Panagiotis Kourtesis , Xia Li , Maria Ascierto , Xuyang Song , Mayukh Das , Neil Howard Segal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02671435
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 128)
Abstract #
128
Poster Bd #
F14
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Keynote-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).
First Author: Luis A. Diaz Jr.
Poster
2017 ASCO Annual Meeting
Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.
First Author: Luis A. Diaz Jr.
Poster
2016 ASCO Annual Meeting
KEYNOTE-177: first-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma.
First Author: Luis A. Diaz Jr.
Poster
2016 Gastrointestinal Cancers Symposium
KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.
First Author: Luis A. Diaz Jr.